Anti-MafA antibody [EPR23582-9]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

MafA also known as musculoaponeurotic fibrosarcoma oncogene homolog A is a transcription factor with a molecular weight of approximately 43 kDa. This protein is expressed mainly in the pancreas particularly in the beta cells of the islets of Langerhans. MafA plays an important role in regulating insulin expression and secretion. High expression of MafA occurs during late-stage beta cell development making it an important marker for mature beta cells. Researchers often study MafA using techniques such as frozen tissue examination and flow cytometry with antibodies against MafA being important tools in these applications.

Biological function summary

MafA controls insulin gene transcription and supports beta cell function and survival. MafA does not function alone; it often forms complexes with other transcription factors like Pdx1 and NeuroD1 facilitating a coordinated regulation of insulin production and secretion. Its activity importantly aligns with the regulation of glucose metabolism responding to changes in glucose levels to ensure proper insulin release from the pancreas. In addition to its standalone role MafA synergizes with other transcription factors to modulate the expression of genes important to the maintenance of beta cell identity and function.

Pathways

The expression and function of MafA are integral to the insulin secretion pathway and the glucose homeostasis pathway. MafA operates alongside proteins like Pdx1 which also regulates insulin gene expression. The interplay between MafA and Pdx1 ensures appropriate response and adaptation of pancreatic beta cells to metabolic demands. Additionally the Wnt signaling pathway may intersect with MafA activity influencing beta cell proliferation and survival. Understanding these pathways is key to grappling with their impact on metabolic health and disease.

Associated diseases and disorders

MafA closely relates to diabetes mellitus particularly type 2 diabetes. Dysfunction or altered expression of MafA impairs insulin production contributing significantly to the pathogenesis of this disorder. Another protein Nkx6.1 often shows disrupted expression alongside MafA in diabetic conditions exacerbating issues in insulin regulation. Furthermore MafA mutations or misregulation may also contribute to gestational diabetes where its interaction with other transcription factors becomes impaired affecting insulin secretion during pregnancy. Researchers continue to study these relationships to develop therapeutic strategies targeting MafA for diabetes management.